Fulcrum Therapeutics (FULC) Scheduled to Post Earnings on Wednesday

Fulcrum Therapeutics (NASDAQ:FULC) will issue its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter.

Fulcrum Therapeutics Trading Up 1.2 %

NASDAQ FULC opened at $3.47 on Thursday. Fulcrum Therapeutics has a 12 month low of $2.87 and a 12 month high of $13.70. The company has a market capitalization of $216.53 million, a PE ratio of -9.80 and a beta of 2.24. The stock has a 50-day simple moving average of $4.46 and a 200 day simple moving average of $6.66.

Wall Street Analysts Forecast Growth

FULC has been the topic of several recent analyst reports. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Leerink Partnrs lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $17.00 to $4.00 in a research note on Friday, September 13th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $10.00 to $2.00 in a report on Thursday, September 12th. Finally, Leerink Partners reiterated a “market perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Hold” and an average target price of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.